Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT04917302
Recruiting Phase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

NCT04917302 · tracked via the Priya Life Science Taiwan tracker
Sponsor
China Medical University Hospital
Phase
Phase 2
Started
2020-10-13
Last updated
2025-02-19

Condition(s) studied

Schizophrenia

Investigational drug(s) / intervention(s)

NMDAE plus AIFAAll Nmdae trials (11) →All AIFA trials (2) →NMDAE plus Placebo Cap

NMDAE plus AIFA: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.

NMDAE plus Placebo Cap: Use of an NMDA enhancer plus placebo as a comparator

Study summary

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia * Are resistant to adequate treatments of at least two antipsychotics * Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 12-week trial * PANSS total score ≥ 70 * Agree to participate in the study and provide informed consent Exclusion Criteria: * DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder * History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study * Clinically significant laboratory screening tests (including blood routine, biochemical tests) * Pregnancy or lactation * Inability to follow protocol

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Psychiatry, China Medical University Hospital Taichung Taiwan Recruiting

More China Medical University Hospital trials in Taiwan

The Taiwan OSA Study Recruiting
Acute Effects of Transcutaneous Electrical Nerve Stimulation at Acupoints on Nociceptive Transmission Recruiting
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Starting soon
Prospective Study of Multi-centers Exploring the Difference of Clinical Impact by Using Respiratory Pathogen ID/AMR Panel (RPIP) Versus Untarget Metagenomic Next-generation Sequencing (mNGS) and Multiplex PCR in Pathogen Identification of Pneumonia Patients in Intensive Care Unit Enrolling by invitation
Segmental Laser Acupuncture for Constipation and Sleep in Patients With Parkinson's Disease Starting soon

Other trials for the same condition

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia Recruiting
Effectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older Adults With Schizophrenia Starting soon
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate Recruiting
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Recruiting
Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04917302 on ClinicalTrials.gov ↗ ← All trials in Taiwan